Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | APP | P05067 | 1/20 | 0.30 |
| ▸ | BACE1 | P56817 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14939614 | 0.93 | LMNA (0.37) | LMNANPSR1SRD5A1CA1CA2 | |
| SCHEMBL14938956 | 0.88 | LMNA (0.43) | LMNANPSR1ACHESRD5A1CA1 | |
| SCHEMBL14939719 | 0.84 | KDM1A (0.36) | SRD5A1CA1CA2CA7CA9 | |
| SCHEMBL14939606 | 0.82 | NPSR1 (0.36) | LMNANPSR1ACHEAPPBACE1 | |
| SCHEMBL14938950 | 0.79 | SRD5A1 (0.36) | LMNANPSR1SRD5A1CA1CA2 | |
| SCHEMBL14940081 | 0.72 | ALDH1A1 (0.44) | NPSR1ACHE | |
| SCHEMBL14939739 | 0.71 | NPSR1 (0.40) | LMNANPSR1 | |
| SCHEMBL14939919 | 0.70 | NPSR1 (0.45) | LMNANPSR1 | |
| SCHEMBL14939181 | 0.69 | ALDH1A1 (0.41) | LMNANPSR1ACHE | |
| SCHEMBL14938813 | 0.69 | ALDH1A1 (0.36) | LMNANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013068785-A1 | INDANONE AND INDANDIONE DERIVATIVES AND HETEROCYCLIC ANALOGS | ACTELION PHARMACEUTICALS LTD (CH) | 2013-05-16 | — | — | WO | disclosed |